MarketBeat
16 Nov 2026, 06:12 UTC · 19h ago
Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer's Gene Therapy Dosing
Impact · against what's priced in
Voyager Therapeutics enters a high-catalyst phase with upcoming tau antibody data and FDA-cleared gene therapy dosing, though the CEO's departure introduces management risk. For Biogen, the failure of BIIB080 confirms the market's skeptical view of new growth drivers, reinforcing the reliance on LEQEMBI's commercial execution.
- BIIB−0.10
Already priced in
- The price assumes
market largely dismisses the bull case for new growth drivers





